By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic test development firm Med BioGene today reported revenues of $593,714 for the first half of 2011, compared to no revenues in the year-ago period.

All revenues during the six months ended June 30 were generated from licensing deals.

For the half-year, the Vancouver, British Columbia-based firm posted net income of $215,034, or break-even on an EPS basis, compared to a loss of $1 million, or $.01 per share, for the first half of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.